Please assess the completion status of the following clinical trial:

Trial Title: MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 6 months of age or younger at randomization (child must be randomized on or before their 6-month birthday)~* Male or female Native American~* General state of good health~* Written informed consent obtained from the participant's parent(s) or legal guardian~Exclusion Criteria:~* Gestational age less than or equal to 35 weeks~* Chronic lung disease of prematurity~* A bleeding diathesis that would preclude IM injections~* Hospitalization at the time of randomization (unless discharge is anticipated within 10 days)~* Active RSV infection (a child with signs/symptoms of respiratory infection must have negative RSV testing) or known prior history of RSV infection~* A documented wheezing episode before enrollment~* Known renal impairment~* Known hepatic dysfunction~* Clinically significant congenital anomaly of the respiratory tract~* Chronic seizure or evolving or unstable neurologic disorder~* Congenital heart disease (CHD) (children with uncomplicated CHD \[e.g., Patent ductus arteriosus, small septal defect\] and children with complicated CHD who are currently anatomically and hemodynamically)~* Known immunodeficiency~* Mother with human immunodeficiency virus infection (unless the child has been proven to be not infected)~* Known allergy to Ig products~* Receipt of palivizumab, Respiratory syncytial virus immunoglobulin, intravenous (RSV-IGIV), or other RSV-specific monoclonal antibody, or any other polyclonal antibody (for example, hepatitis B immunoglobulin, IVIG) within 3 months prior to randomization~* Anticipated use of palivizumab or IVIG during the study (blood transfusions permitted)~* Previous receipt of RSV vaccines~* Participation in other investigational drug product studies~* Any medical or social condition which, in the opinion of the investigator, would adversely affect monitoring the infant~* Inability to complete the study follow-up period through up to 5 years of age

- Gender: ALL
- Minimum Age: 0 Months
- Maximum Age: 6 Months
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive IM dose of placebo matched to motavizumab every 30 days for a maximum of 5 injections (on Days 0, 30, 60, 90, and 120) during the the RSV season.
- Motavizumab (Type: ACTIVE_COMPARATOR): Participants will receive IM dose of motavizumab 15 milligram/Kilogram (mg/kg) every 30 Days for a maximum of 5 injections (on Days 0, 30, 60, 90, and 120) during the RSV season.

Based on this trial design, predict the completion outcome and termination type (if applicable).